Investors Unite Against Soleno Therapeutics Over Alleged Clinical Trial Fraud
Investors Unite Against Soleno Therapeutics Over Alleged Clinical Trial Fraud
In a significant turn of events, purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities are being reminded about a pending securities class action by law firm Levi & Korsinsky, LLP. This lawsuit has emerged following serious allegations regarding the integrity of clinical trials that were crucial for the FDA approval of the company’s primary product, DCCR (marketed as VYKAT XR). This drug is specifically designed to treat hyperphagia in patients suffering from Prader-Willi syndrome.
Overview of the Class Action
The class action seeks financial restitution for those investors who bought shares in Soleno between March 26, 2025, and November 4, 2025. Plaintiffs may be eligible to recover losses without any out-of-pocket expenses. Investors are advised to connect with Joseph E. Levi, Esq. at the provided contact information for support regarding their potential claims. However, it’s important to note that May 5, 2026, marks the deadline for seeking lead plaintiff status in this case.
Importance of Clinical Integrity
A pharmaceutical company’s ability to market a drug hinges significantly on receiving FDA approval, which requires strong evidence of safety and efficacy gained through well-structured clinical trials. In Soleno’s case, the commercial viability of DCCR rests largely on one pivotal study, specifically the randomized withdrawal phase of Study C602. If the data from this study proves to be unreliable, the entire basis for the drug’s approval and subsequent commercial launch could be severely jeopardized.
The allegations put forth in the lawsuit claim that Soleno’s Phase 3 clinical trials were fraught with systematic issues that management either knew about or ignored. Here are some key points highlighting the alleged deficiencies:
- - Limited Sample Size: The pivotal study had a mere 77 participants, which is considered an unusually small sample size, possibly skewed due to a concentration on a single clinical site.
- - Initial Trial Results: The original 13-week Phase 3 trial failed to meet its primary objective regarding hyperphagia improvement, raising further concerns about the drug’s efficacy.
- - Placebo Bias: Investigators reportedly noted significant placebo bias attributed to side effects like hypertrichosis and edema, which were visible rather than blinding.
- - Expert Opinions: Many independent investigators have expressed strong skepticism about the trial’s conduct and indicated they had no plans to prescribe the medication.
- - Deterioration of Safety Profile: The trial allegedly obscured issues such as increasing markers for prediabetes and diabetes, raising flags about long-term safety.
Safety Concerns Around DCCR
The lawsuit also sheds light on substantial safety concerns, particularly regarding the drug’s mechanism of action. Diazoxide, the active ingredient, is inherently linked to fluid retention, which reportedly led to severe symptoms in two patients during the trial, possibly likened to heart failure. Yet, these adverse effects seemed to be downplayed in communications with investors. Despite finding that the prevalence of edema increased over extended use, management proclaimed a “well-established safety profile” and asserted that no new safety issues had surfaced in the post-marketing phase.
Joseph E. Levi, Esq. of Levi & Korsinsky has articulated the gravity of the lawsuit, noting, “The complaint raises serious questions about whether investors received accurate information regarding the integrity of the clinical data underpinning DCCR's approval and commercial launch.”
In light of these developments, current and prospective investors should be monitoring this case closely as it unfolds, assessing any implications for their financial interests in Soleno Therapeutics. Not only does this situation underscore the necessity of clinical trial transparency but also highlights the potential consequences of reputational damage on a biotech firm’s market performance.
Conclusion
As the legal battle progresses, those impacted by the alleged fraud are urged to seek legal guidance. The unfolding story of Soleno Therapeutics serves as a crucial reminder about the responsibility that pharmaceutical companies have in ensuring the integrity of their clinical trials, which ultimately protects investors and patients alike.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.